Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRS total choline as early predictor of response to neoadjuvant chemotherapy in early breast cancer
2011-006259-12Phase 2Completed
- Sponsor
- Institut Jules Bordet
- Start
- May 2012
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of epirubicin in breast adenocarcinoma, sponsored by Institut Jules Bordet. Primary endpoints: Radiological tumour response by RECIST after anthracycline-based chemotherapy and Pathological response at surgery. Started May 2012; status: completed.
02
Drugs
epirubicin
03
Conditions
breast adenocarcinoma
Beyond the preview
Go deeper on 2011-006259-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006259-12.